BRIDGEWATER, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) — Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 third quarter financial results on Thursday, November 14, 2019, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call to discuss the results as follows:
|Date||Friday, November 15, 2019|
|Time||8:30 a.m. EST|
|Toll free (U.S.)||(866) 672-5029|
|Webcast (live and replay)||www.osmotica.com under the “Investor & News” section|
The webcast will be archived for 30 days at the aforementioned URL.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio, and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
E: [email protected]
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Laredo Petroleum, Inc. – LPI - September 27, 2020
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva Pharmaceuticals Industries Limited of Class Action Lawsuit and Upcoming Deadline – TEVA - September 27, 2020
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oak Street Health, Inc. – OSH - September 27, 2020